Genematrix Begins Phase 1 Trial of Domestically Developed Hepatitis A Vaccine
Predicted impact: Medium
Phase 1 start for a hepatitis A vaccine; early-stage, small company with market value about 29.6 billion won.
Predicted impact: Medium
Phase 1 start for a hepatitis A vaccine; early-stage, small company with market value about 29.6 billion won.
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.